Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in


Characterization of Protein and Protein Aggregates using Temperature-controlled Hollow-Fiber Flow-FFF
Trevor Havard, Florian Meier, Evelin Moldenhauer, Soheyl Tadjiki, Thorsten Klein

Reproducibilty Improvements in Field Flow Fractionation can be achieved on two fronts. Instrument design and control, the system used in for this poster is does not require flow controllers or switching valves and there for produces the same conditions in every case. Fractionater design, the design of the cartridges used in this poster maintain excellent conditions to maintain constant pressure at the membrane removing unwanted effects of sale relaxation above the membrane s

More information
Specificity of highly potent miRNA inhibitors
Barbara Roberston, Andrew Dalby, Yuriy Fedorov, Jon Karpilow, Anastasia Khvorova, Devin Leake, Annaleen Vermeulen

Specificity of highly potent miRNA inhibitors

More information
Lisha Allen, Yi Mi, Muhammad Abbas, Wolfgang Richter, and Sean Hu

We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins

More information
Toward a Comprehensive Bottom-up and Top-down Analysis of the NIST Reference Monoclonal Antibody
Chris Becker1, Eric Carlson1, Wilfred Tang1, Yong Kil1, Marshall Bern1, John Schiel2, Lisa Kilpatrick2, Trina Formolo2

Development of ADC and other therapeutic proteins require careful characterization of sequence, post-translational modifications, sequence variants, and degradants. In this study, a NIST mAb interim reference material was analyzed by new bioinformatics tools (Byonic™, Byologic®, and Byomap™) allowing one to efficiently identify and quantify modifications down to trace levels.

More information
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
T. Roux1, M. Badol1, N. Douayry1, L. Sergeant1, E.Trinquet1, F. Degorce1, S. Milhas2, S. Betzi2, C. Derviaux2, C. Eydoux3, J. Letienne2, A. Lugari2, Y. Collette2, J-C. Guillemot3 et X. Morelli2

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

More information
Artificial Multi-Gene Expression Systems Design Service for Natural Compound Formation and Hetero Protein Complexes
Bernauer, Hubert, Gregor Zipf and Josef Maier

Drug discovery of natural compounds drug development and drug target analyses as well as bioproduction can benefit from artificial genetic systems and constructions. The direction in which genes are to be developed is written in the genomes. Synthesis oriented genomic analyses of codon bias and tRNA adaption analyses are prerequisites for generating adaptive, highly functional genes.

More information
Next Generation Multivalent PRINT Nanoparticle Vaccine Targeting Pneumococcal Disease
Shyam Rele,1 RiLee Robeson,1 Anton Beletskii,1 Jeremy Hansen,1 Meredith Earl,1 Gabe Fawcett,1* Marquita Lilly,1 Joseph Marchand,1 Michele Stone,1 Camille Bernasconi,1 Jinny Conley,1 Michael Hunter,1 Ramya Yadavalli,1 Nicole Meyer,1 Lara Kelly,1 Ben Yerxa,1 Jeff Maisonneuve,2 Mark Alderson,2 Frank Malinoski1

A new generation PRINT nanoparticle Pneumococcal vaccine matrix has been designed to mimic size and structural aspects of bacterial pathogens to efficiently present and deliver polysaccharide and protein antigens to elicit robust immune responses.

More information
Factors influencing mAb aggregation in mammalian cell culture
Albert Paul, Melanie Leitte, Franziska Schandock, Rene Handrick and Friedemann Hesse

Analysis of mAb aggregate formation in Chinese hamster ovary (CHO) cell culture.

More information
Developing Functional Monoclonal Antibodies for Beta-3 Adrenergic Receptor
Miao Tan and Helena Mancebo

Our preliminary data showed that several mAb clones specifically bound to the receptor while increasing the receptor function by acting as agonists.

More information
Early Immunogenicity Risk Mitigation
Chloé Ackaert, Brecht Hoedemaekers, Sofie Pattijn and Philippe Stas

The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems. .

More information
<< 1 2 3 >>
Showing Results 1 - 10 of 28
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos